Drugs / D026
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04703374 | Sep 2020 → Sep 2021 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT03558425 | Jun → Sep 2018 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03444402 | Mar → May 2018 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04703374 ↗ |
| Known as | Nexium | “D026(Nexium 40mg)” NCT03444402 ↗ |